Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The potential of PARP inhibitors in new cancer groups and in combination with other treatments

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.06.19
Views: 296

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA

Dr Jennifer Litton talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about using PARP inhibitors in other tumour types, outside of ovarian and breast cancer, and in combination with other treatments.

She explains that combinations with PARP inhibitors are particularly exciting with immunotherapy highlighted as a promising combination option.

This programme has been supported by an unrestricted educational grant from Pfizer.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation